Overview

Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL)

Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to test if there is bioequivalence between the insulin aspart 100 U/mL (U100) formulation and the new insulin aspart 200 U/mL (U200) formulation.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Insulin
Insulin Aspart
Insulin degludec, insulin aspart drug combination
Insulin, Globin Zinc
Insulin, Long-Acting